Influence of paroxetine and hydroxyzine hydrochloride therapy on anxiety-depressive disorders and platelet serotonin level in CAD patients

Objective. Open, comparative, randomized study of efficiency, safety and assessment of influence of paroxetine and hydroxyzine hydrochloride therapy on platelet serotonin level in patients with coronary artery disease (CAD) and comorbid anxiety-depressive disorders were examined. Design and methods. We included 40 patients with chronic CAD and comorbid anxiety-depressive disorders, confirmed according to ICD-10. Patients with score more than 18 by Hamilton’s scale of anxiety and depression were enrolled. Results. We observed significant decrease Hamilton’s scale scores after 4 weeks of treatment, and after 8 weeks of treatment the reduction reached 50 %. Side effects were registered in both groups and quickly passed after the drug withdrawal. Platelet serotonin level decreased significant during paroxetine therapy. Conclusion. Treatment by paroxetine and hydroxyzine hydrochloride was associated with high anti-anxiety and anti-depressive activity. Use of paroxetine was associated with significant reduction of platelet serotonin level.

depression, anxiety, coronary artery disease, hydroxyzine hydrochloride, paroxetine

1. Ariyo A.A., Haan M., Tangen C.M. et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Colloborative Research Group // Circulation. – 2000. – Vol. 102, № 15. – Р. 1773-1779.

2. Kawachi I., Colditz G.A. Prospective study of phobic anxiety and risk of coronary heart disease in men // Circulation. – 1994. – Vol. 89, № 5. – P. 1992-1997.

3. Ellis J., Eagle K., Kline-Rogers E., Erickson S.R. Depressive symptoms and treatment after acute coronary syndrome // Int. J. Cardiol. – 2005. – Vol. 99, № 33. – P. 443-447.

4. Hamilton M. Hamilton anxiety scale // In: Gue W. ed. ECDEU Assessment manual for psycholopharmacology. Rev. Ed. - Washington DC: US Department of Health, Education and Welfare, 1976. – P. 193-198.

5. Hamilton M. A rating for depression // J. Neurol. Neurosurg. Psych. – 1960. – Vol. 23. – P. 56-61.

6. Efron B. Forcing a sequential experiment to be balanced // Biometrica. – 1971. – Vol. 58. – P. 403-417.

7. Ressler K.J., Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders // Depress. Anxiety. – 2000. – Vol. 12, suppl. 1. – P. 2-19.

8. Brewerton T.D., Lydiard M.R., Johnson M.R. et all. CSF Serotonin: diagnostic and seasonal differences, Abstract № 358 // In: New research and abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995. - Miami, Fla., 1995. – P. 151.

9. Iny L.J., Pecknold J., Suranyi-Cadotte B.E. et all. Studies of a nerochemical link between depression, anxiety and stress from [3H] imipramine and [3H] paroxetine binding n human platelets // Biol. Psychiatry. – 1994. – Vol. 36, № 5. – P. 281-291.

10. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine // Prog. Neurobiol. – 2001. – Vol. 63, № 6. – Р. 637-672.

11. Millan M.J. The neurobiology and control of anxious states // Prog. Neurobiol. – 2003. – Vol. 70, № 2. – Р. 83-244.

12. Nelson J.C., Kennedy J.S., Pollock B.G. et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease // Am. J. Psychiatry. – 1999. – Vol. 156, № 7. – P. 1024-1028.

13. Rocca P., Fonzo V., Scotta M. et al. Paroxetine efficacy in the treatment of generalized anxiety disorders // Acta Psychiatr. Scand. – 1997. – Vol. 95, № 5. – Р. 444-450.

14. Regan K.L. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review // J. Cardiovasc. Nurs. – 2008. – Vol. 23, № 6. – Р. 489-496.

15. Llorca P.M., Spadone C., Sol O. et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study // J. Clin. Psychiatry. – 2002. – Vol. 63, № 11. – Р. 1020-1027.

16. Figueras G., Pérez V., San Martino O. et al. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos // Biol. Psychiatry. – 1999. – Vol. 46, № 4. – Р. 518-524.

17. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies // J. Clin. Psychiatry. – 2001. – Vol. 62, suppl. 12. – P. 16-23.